巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Guardant Health

    GH
    42.990
    4.400
    11.40%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Guardant Health - 延遲價格・最後更新於 27/05 12:14
    最高位
    43.270
    最低位
    39.550
    開市價
    --
    前收市價
    38.590
    成交量(千)
    34.58
    成交額(百萬)
    12.75
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    4,381.68
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    133.820 - 27.650
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Guardant Health
    證券代碼
    GH.US
    所屬板塊
    Diagnostics & Research
    公司業務
    Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
    發行量
    101767446
    公司總部
    505 Penobscot Drive
    公司網址
    https://www.guardanthealth.com
    公司電郵
    investors@guardanthealth.com
    公司電話
    +1 855 698-8887
    暫無內容

    關於

    Guardant Health(GH.US)所屬的行業板塊為Diagnostics & Research。
    Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
    詳細公司背景可參考: https://www.guardanthealth.com